Fisetin-loaded nanocochleates: formulation, characterisation, in vitro anticancer testing, bioavailability and biodistribution study

Bibliography

• Bothiraja C, Pawar AP. Improved bioavailability of orally administered andrographolide from pH-sensitive nanoparticles. Eur J Drug Metab Pharmacokinet 2011a;35(3-4):123-9
   PubMed Web of Science ®Google Scholar
• Botelho MA, Rao VS, Carvalho CB, et al. Lippia sidoides and Myracrodruon urundeuva gel prevents alveolar bone resorption in experimental periodontitis in rats. J Ethnopharmacol 2007;113(3):471-8
   PubMed Web of Science ®Google Scholar
• Botelho MA, Rao VS, Montenegro D, et al. Effects of a herbal gel containing carvacrol and chalcones on alveolar bone resorption in rats on experimental periodontitis. Phytother Res 2008;22(4):442-9
   PubMed Web of Science ®Google Scholar
• Szliszka E, Helewski KJ, Mizgala E, Krol W. The dietary flavonol fisetin enhances the apoptosis-inducing potential of TRAIL in prostate cancer cells. Int J Oncol 2011;39(4):771-9
   PubMed Web of Science ®Google Scholar
• Liu W, Tian R, Hu W, et al. Preparation and evaluation of self-microemulsifying drug delivery system of baicalein. Fitoterapia 2012;83(8):1532-9
   PubMed Web of Science ®Google Scholar
• Jain S, Jain AK, Pohekar M, Thanki K. Novel self-emulsifying formulation of quercetin for improved in vivo antioxidant potential: implications for drug-induced cardiotoxicity and nephrotoxicity. Free Radic Biol Med 2013;65(12):117-30
   PubMedGoogle Scholar
• Zhao L, Zhang L, Meng L, et al. Design and evaluation of a self-microemulsifying drug delivery system for apigenin. Drug Dev Ind Pharm 2013;39(5):662-9
   PubMed Web of Science ®Google Scholar
• Tang J, Xu N, Ji H, et al. Eudragit nanoparticles containing genistein: formulation, development and bioavailability assessment. Int J Nanomed 2011;6:2429-35
   PubMed Web of Science ®Google Scholar
• Puhl AC, Fagundes M, Santos KC, et al. Preparation and characterization of polymeric nanoparticles loaded with the flavonoid luteolin by using factorial design. Int J Drug Deliv 2011;3(4):683-98
   Google Scholar
• Tan Q, Liu WD, Guo CY, Zhai GX. Preparation and evaluation of quercetin-loaded lecithin-chitosan nanoparticles for topical delivery. Int J Nanomed 2011;6(8):1621-30
   PubMedGoogle Scholar
• Arai Y, Watanabe S, Kimira M, et al. Dietary intakes of flavonols, flavones and isoflavones by Japanese women and the inverse correlation between quercetin intake and plasma LDL cholesterol concentration. J Nutr 2000;130(9):2243-50
   PubMed Web of Science ®Google Scholar
• Inkielewicz-Stepniak I, Radomski MW, Wozniak M. Fisetin prevents fluoride-and dexamethasone-induced oxidative damage in osteoblast and hippocampal cells. Food Chem Toxicol 2012;50(3-4):583-9
   PubMed Web of Science ®Google Scholar
• Cho Y, Chung JH, Do HJ, et al. Effect of fisetin supplementation on hepatic lipogenesis and glucose metabolism in Sprague-Dawley rats fed on a high fat diet. Food Chem 2013;139(1-4):720-7
   PubMed Web of Science ®Google Scholar
• Ju YK, Young KJ, Won J, Myeong JN. Fisetin induces apoptosis in Huh-7 cells via downregulation of BIRC8 and Bcl2L2. Food Chem Toxicol 2010;48(8-9):2259-64
   PubMed Web of Science ®Google Scholar
• Raygude KS, Kandhare AD, Ghosh P, Bodhankar SL. Anticonvulsant effect of fisetin by modulation of endogenous biomarkers. Biomed Prevent Nutr 2012;2(3):215-22
   Google Scholar
• Touil YS, Seguin J, Scherman D, Chabot GG. Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice. Cancer Chemother Pharmacol 2011a;68(2):445-55
   PubMed Web of Science ®Google Scholar
• Tripathi R, Samadder T, Gupta S, et al. Anticancer activity of a combination of cisplatin and fisetin in embryonal carcinoma cells and xenograft tumors. Mol Cancer Ther 2011;10(2):255-68
   PubMed Web of Science ®Google Scholar
• Yu SH, Yang PM, Peng CW, et al. Securin depletion sensitizes human colon cancer cells to fisetin-induced apoptosis. Cancer Lett 2011;300(1):94-104
   Google Scholar
• Adhami VM, Syed DN, Khan N, Mukhtar H. Dietary flavonoid fisetin: a novel dual inhibitor of PI3K/Akt and mTOR for prostate cancer management. Biochem Pharmacol 2012;84(10):1277-81
   PubMed Web of Science ®Google Scholar
• Chien CS, Shen KH, Huang JS, et al. Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells. Mol Cell Biochem 2010;333(1-2):169-80
   PubMed Web of Science ®Google Scholar
• Khan N, Asim M, Afaq F, et al. A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice. Cancer Res 2008;68(20):8555-63
   PubMed Web of Science ®Google Scholar
• Mignet N, Seguin J, Ramos Romano M, et al. Development of a liposomal formulation of the natural flavonoid fisetin. Int J Pharm 2012;423(1):69-76
   PubMed Web of Science ®Google Scholar
• Touil YS, Auzeil N, Boulinguez F, et al. Fisetin disposition and metabolism in mice: identification of geraldol as an active metabolite. Biochem Pharmacol 2011b;82(11):1731-9
   PubMed Web of Science ®Google Scholar
• Seguin J, Brulle J, Boyer R, et al. Liposomal encapsulation of the natural flavonoid fisetin improves bioavailability and antitumor efficacy. Int J Pharm 2013;444(1-2):146-54
   PubMed Web of Science ®Google Scholar
• Ragelle H, Crauste-Manciet S, Seguin J, et al. Nanoemulsion formulation of fisetin improves bioavailability and antitumour activity in mice. Int J Pharm 2012;427(2):452-9
   PubMed Web of Science ®Google Scholar
• Crauste-Manciet S, Larquet E, Khawand K, et al. Lipidic spherulites: formulation optimisation by paired optical and cryoelectron microscopy. Eur J Pharm Biopharm 2013; In press
   PubMed Web of Science ®Google Scholar
• Capek I. Degradation of kinetically-stable o/w emulsions. Adv Colloid Interface Sci 2004;107(2-3):125-55
   PubMed Web of Science ®Google Scholar
• Zarif L, Graybill J, Perlin D, Mannino RJ. Cochleates: new lipid based drug delivery system. J Liposome Res 2000;10(4):523-38
   Web of Science ®Google Scholar
• Zarif L. Elongated supramolecular assemblies in drug delivery. J Control Release 2002;81(1-2):7-23
   PubMed Web of Science ®Google Scholar
• Delmarre D, Lu R, Tatton N, et al. Cochleate-mediated delivery. Drug Deliv Technol 2004;9(4):64-9
   Google Scholar
• Zarif L, Perlin D. Amphotericin B nanocochleates: from formulation to oral efficacy. Drug Deliv Technol 2002;2(4):34-7
   Google Scholar
• Pham TT, Loiseau PM, Barratt G. Strategies for the design of oral bioavailable antileishmanial treatments. Int J Pharm 2013;454(1):539-52
   PubMedGoogle Scholar
• Paleos CM, Tsiourvas D, Sideratou Z. Preparation of multicompartment lipid-based systems based on vesicle interactions. Langmuir 2012;28(5):2337-46
   PubMed Web of Science ®Google Scholar
• Acevedo R, Callico A, Del Camo J, et al. Intranasal administration of peroteoliposome-derived cochleates from Vibrio cholera induced mucosal and systemic immune responses in mice. Methods 2009;49(4):309-15
   PubMed Web of Science ®Google Scholar
• Shaikh K, Pawar A. Mucoadhesive nanoliposomal formulation for vaginal delivery of an antifungal. Drug Dev Ind Pharm 2012
   Web of Science ®Google Scholar
• Evans CC, Zasadzinski J. Encapsulating vesicles and colloids from cochleate cylinders. Langumuir 2003;19(8):3109-13
   Web of Science ®Google Scholar
• Bothiraja C, Pawar AP. Andrographolide, a novel bioactive phytoconstituent encapsulated in sustained release biodegradable nanoparticles. Int J Nanotechnol 2011b;8(8-9):764-78
   Web of Science ®Google Scholar
• Bothiraja C, Kapare HS, Pawar AP, Shaikh KS. Development of plumbagin-loaded phospholipid-Tween® 80 mixed micelles: formulation, optimization, effect on breast cancer cells and human blood/serum compatibility testing. Ther Deliv 2013;4(10):1247-59
   PubMedGoogle Scholar
• Tong S, Xiang B, Dong D, Qi X. Enhanced antitumor efficacy and decreased toxicity by self-associated docetaxel in phospholipid-based micelles. Int J Pharm 2012;434(1-2):413-19
   PubMedGoogle Scholar
• Shia CH, Tsai SY, Kuo SC, et al. Metabolism and pharmacokinetics of 2,3',4',7-tetrahydroxyflavone (fisetin), 5-hydroxyflavone and 7-hydroxyflavone and antihemolysis effects of fisetin and its serum metabolites. J Agric Food Chem 2009;57(1):83-9
   PubMed Web of Science ®Google Scholar
• Gonzaga LW, Botelho MA, Queiroz DB, et al. Nanotechnology in hormone replacement therapy: Safe and efficacy of transdermal estriol and estradiol nanoparticles after 5 years follow-up study. Lat Am J Pharm 2012;31(3):442-50
   Web of Science ®Google Scholar
• Botelho MA, Martins JG, Ruela RS, et al. Nanotechnology in ligature-induced periodontitis: protective effect of a doxycycline gel with nanoparticles. J Appl Oral Sci 2010;18(4):335-42
   PubMed Web of Science ®Google Scholar
• Botelho MA, Martins JG, Ruela RS, et al. Protective effect of locally applied carvacrol gel on ligature-induced periodontitis in rats: a tapping mode AFM study. Phytother Res 2009;23(10):1439-48
   PubMed Web of Science ®Google Scholar
• Bennet D, Kim S. A transdermal delivery system to enhance quercetin nanoparticle permeability. J Biomater Sci Polymer Ed 2013;24(2):185-209
   PubMed Web of Science ®Google Scholar
• Touil YS, Fellous A, Scherman D, Chabot GG. Flavonoid-induced morphological modifications of endothelial cells through microtubule stabilization. Nutr Cancer 2009;61(3):310-21
   PubMed Web of Science ®Google Scholar
• Marone PA, Elsmore SK, Sandulow J, Mannino RJ. Structural determinants of divalent cation-Induced phosphatidylserine cochleate crystallization. Microsc Microanal 2005;11(2):1244-5
   Google Scholar
• Zarif L. Cochleates as nanoparticular drug carriers. In: Torchilin VP, editor. Nanoparticulates as drug carriers. Imperial College Press; London; 2006. p. 349-66
   Google Scholar
• Delmarre D, Gould-Fogerite S, Mannino RJ. Formulation of hydrophobic drugs into cochleate delivery vehicles: A simplified protocol & bioral TM formulation kit. Drug Deliv Technol 2004;4(1):1-10
   Google Scholar
• Jin T, Zarif L, Raphael M. Nanocochleate formulations process of preparation and method of delivery of pharmaceutical agents. US 6,153,217; 2000
   Google Scholar
• Newton C, Pangborn W, Nir S, Papahadjopoulos D. Specificity of Ca++ and Mg++ binding to phosphatidylserine vesicles and resultant phase changes of bilayer membrane structure. Biochem Biophys Acta 1978;506(2):281-7
   PubMed Web of Science ®Google Scholar
• Lichtenberger LM, Graziani LA, Dial EJ, et al. Role of surface-active phospholipids in gastric cytoprotection. Science 1983;219(4590):1327-9
   PubMed Web of Science ®Google Scholar
• Fahr A, Van HP, Kuntsche J, Leigh ML. Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery? J Liposome Res 2006;16(3):281-301
   PubMed Web of Science ®Google Scholar
• Leonhard V, Alasino RV, Bianco ID, et al. Self -assembled micelles of monosialogangliosides as nanodelivery vehicles for taxanes. J Control Release 2012;162(3):619-27
   PubMed Web of Science ®Google Scholar
• Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv Drug Deliv Rev 2001;47(1):55-64
   PubMed Web of Science ®Google Scholar
• Soma D, Kitayama J, Ishigami H, et al. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. J Surg Res 2009;155(1):142-6
   PubMed Web of Science ®Google Scholar